


WHAT IS CLAIMED IS:

1. A compound of formula I



in which

Ring A is (C₃-C₈)-cycloalkyl ;

R1, R2, R4, R5, independently of one another, are H, F, Cl, Br, CF₃, OCF₃, CN, CH₃, or OCH₃;

R3 is H or CH₃;

X is (C₁-C₂)-alkyl where, in the alkyl group, one carbon atom is replaced by an oxygen atom;

Y is (C₁-C₂)-alkyl where, in the alkyl group, one carbon atom is replaced by an oxygen atom;

or a physiologically acceptable salt of a compound of formula I.

2. A compound as claimed in claim 1, wherein

Ring A is cyclohexyl;

R1, R2 are, independently of one another, H, F, Cl, Br, CF₃, OCF₃, CN, CH₃, or OCH₃; and

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R3, R4, R5 are, independently of one another, H or CH₃.

3. A compound as claimed in claim 2, wherein

R1 is H, CH₃, or OCH₃; and

R2 is H, F, Cl, Br, CF₃, OCF₃, CN, CH₃, or OCH₃.

4. A compound as claimed in claim 3, wherein

R1, R3, R4, are, independently of one another, H;

R2 is H, F, Cl, Br, CF₃, OCF₃, CN, CH₃, or OCH₃; and

R5 is CH₃.

5. A compound as claimed in claim 3, wherein

R1, R3 are, independently of one another, H;

R2 is H, F, Cl, Br, CF₃, OCF₃, CN, CH₃, or OCH₃;

R4 is CH₃; and

R5 is CH₃.

6. A compound as claimed in claim 3, wherein

R2 is H, F, Cl, CF₃, OCF₃, CH₃, or OCH₃;

R3 is H;

R4 is H or CH₃; and

R5 is CH₃.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. A compound as claimed in claim 6, wherein

R1 is H or CH₃;

R2 is F, OCF₃, CH₃, or OCH₃;

8. A compound as claimed in claim 7, wherein

R1 is H;

9. A compound as claimed in claimed in claim 1 wherein the compound is chosen from:

2-{3-[2-(4-Fluorophenyl)oxazol-4-ylmethoxy]cyclohexyloxy}-6-methylbenzoic acid;

(+)-cis-2-(3-(2-(4-Fluorophenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid;

cis-2-(3-(2-(4-Methoxyphenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid

cis-2-Methyl-6-[3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid;

cis-2-Methyl-6-[3-(2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid;

cis-2-(3-[2-(4-Fluorophenyl)-5-methyloxazol-

4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-cyclohexyloxymethyl}-6-methylbenzoic acid;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2-{1*R*,3*S*-3-[2-(3-Methoxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3-Trifluoromethylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3-Chlorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(4-Chlorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3-Methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3,4-Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(2,4-Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(2-Methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-{1*R*,3*S*-3-[2-(3,4-Dimethoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

2-Methyl-6-[1*R*,3*S*-3-(5-methyl-2-phenyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2-Methyl-6-[1*R*,3*S*-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid; and
2-{1*R*,3*S*-3-[2-(4-Methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid.

10. A compound as claimed in claimed in claim 1 wherein the compound is chosen from:
- (+)-cis-2-(3-(2-(4-Fluorophenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid;
- cis-2-(3-(2-(4-Methoxyphenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid;
- cis-2-(3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl)-6-methylbenzoic acid;
- 2-{1*R*,3*S*-3-[2-(3-Methoxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-cyclohexyloxymethyl}-6-methylbenzoic acid;
- 2-{1*R*,3*S*-3-[2-(3-Methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;
- 2-{1*R*,3*S*-3-[2-(3,4-Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;
- 2-{1*R*,3*S*-3-[2-(2,4-Dimethylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;
- 2-{1*R*,3*S*-3-[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2-Methyl-6-[1*R*,3*S*-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid; and
2-{1*R*,3*S*-3-[2-(4-Methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid.

11. A compound as claimed in claimed in claim 1 wherein the compound is chosen from:
(+)-cis-2-(3-(2-(4-Fluorophenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid.
cis-2-(3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl)-6-methylbenzoic acid.
2-{1*R*,3*S*-3-[2-(3-Methoxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-cyclohexyloxymethyl}-6-methylbenzoic acid.
2-{1*R*,3*S*-3-[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid.
2-Methyl-6-[1*R*,3*S*-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid.
12. (+)-cis-2-(3-(2-(4-Fluorophenyl)oxazol-4-ylmethoxy)cyclohexyloxymethyl)-6-methylbenzoic acid.
13. cis-2-(3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl)-6-methylbenzoic acid.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

14. 2-{1*R*,3*S*-3-[2-(3-Methoxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-cyclohexyloxymethyl}-6-methylbenzoic acid.
15. 2-{1*R*,3*S*-3-[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyloxymethyl}-6-methylbenzoic acid.
16. 2-Methyl-6-[1*R*,3*S*-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoic acid.
17. A pharmaceutical, comprising at least one compound as claimed in claim 1; and a pharmaceutically acceptable carrier.
18. A pharmaceutical, comprising:
at least one compound as claimed in claim 1;
at least one further active compound; and
a pharmaceutically acceptable carrier.
19. A pharmaceutical, comprising:
at least one compound as claimed in claim 1;
at least one lipid- or triglyceride-lowering active compound; and
a pharmaceutically acceptable carrier.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

20. A method of treating a lipid metabolism disorder, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
21. A method of treating type II diabetes, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
22. A method of treating syndrome X, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
23. A method of treating disturbed glucose tolerance, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
24. A method of treating eating disorders, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
25. A method of treating obesity, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

26. A method of treating cardiomyopathy, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
27. A method of treating cardiac insufficiency, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
28. A method of treating osteoporosis, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
29. A method of treating atherosclerosis, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
30. A method of treating Alzheimer's disease, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

31. A method of treating inflammation, comprising:
administering to a host in need of such treatment an effective amount of at least one compound as claimed in claim 1.
32. The method of treating a lipid metabolism disorder of claim 20, further comprising administering to a host in need of such treatment an effective amount of at least one further active compound.
33. The method of treating type II diabetes of claim 21, further comprising administering to a host in need of such treatment an effective amount of at least one further active compound.
34. The method of treating syndrome X of claim 22, further comprising administering to a host in need of such treatment an effective amount of at least one further active compound.
35. A process for preparing a pharmaceutical, comprising:
mixing at least one compound as claimed in claim 1 with a pharmaceutically acceptable carrier to form a mixture; and
bringing this mixture into a form suitable for administration to form the pharmaceutical.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com